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Abstract
The underlying pathology of most cardiovascular diseases (CVDs) such as 
coronary artery disease, high blood pressure, and stroke involves decreased cardio-
vascular contractility and anatomic alterations in cardiovascular structures. Nitric 
oxide (NO) regulates vascular tone and contractile function of myocardium and main-
tains blood vessel homeostasis. Interestingly, the effect of NO is like a double-edged  
sword in the body. Insufficient NO causes hypertension and atherosclerosis, while 
an overproduction of NO may foster inflammation and cause heart infarction and 
shock. In addition, growing evidences have shown that oxidative stress plays pivotal 
roles in the initiation and progression of CVDs. This chapter will discuss in detail 
the roles NO plays in the cardiovascular system under both physiological and patho-
logical conditions. We will focus on: (1) the molecular mechanism of cardiovascular 
contraction, (2) NO/Ca2+-induced muscle relaxation, (3) NO-related structural 
change in blood vessels, and (4) redox balance in the cardiovascular system. The 
relationships between these molecular mechanisms and the characteristics of CVDs 
will be highlighted.
Keywords: cardiovascular diseases, muscle contraction and relaxation,  
cytoskeleton, nitric oxide, nitroso-redox balance
1. Introduction
Cardiovascular diseases (CVDs), i.e., ischemic heart disease and stroke, remain 
the leading cause of death in the past decades around the world, especially in the 
developed countries [1]. CVDs can start from risk factors that may cause local vas-
cular lesion and end up with systematic complications, which lead to organ failure 
and death. Thus, understanding the biochemistry of events involved in the whole 
process of CVD progression is crucial to prevent and treat the disease.
Epidemiological data show that various factors are associated with the increase 
of cardiovascular morbidity and mortality, including hypertension, smoking, 
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hypercholesterolemia, diabetes mellitus, obesity, stress, low fruit and vegetable 
dietary, lack of regular exercise, and abnormal sleep [2]. Current therapeutic strate-
gies mainly focus on reducing patients’ blood pressure, restoring redox balance, 
controlling cholesterol, and implementing physical activity programs [3]. In this 
chapter, we explore the physiological and pathological events in the cardiovascular 
system from the molecular biology’s perspectives. Molecular mechanism of muscle 
contraction and relaxation in the cardiovascular system will be discussed first. 
Then, we will delve into the biological effects of Nobel Prize molecule nitric oxide 
(NO), the most important vasodilator in the body. In addition, due to the inspiring 
clinical outcomes of using isosorbide dinitrate (an NO stimulus) and hydralazine 
(an antioxidant) to treat patients with symptomatic congestive heart failure [4], we 
will also discuss how nitroso-redox balance mediates cardiovascular functions.
2. Muscle contraction and relaxation
2.1 Sliding filament theory
Skeletal, cardiac, and smooth muscles have different structures and regulatory 
mechanisms, but they share the same molecular mechanism of contraction and 
relaxation, i.e., the relative sliding between myofilaments [5]. To understand how 
the heart beats and how blood vessels regulate their tones, it is important to look 
into the subcellular structure of these tissues (Figure 1).
Heartbeat relies on myofibrils, a fiber bundle structure that abounds in cardio-
myocyte (Figure 1c). When a number of myofibrils are highly aligned, sarcomere, 
a repeat unit in the myofibril, can be observed under the microscope. Sarcomere 
is the basic unit for motion. Two most important proteins in the sarcomere are: 
myosin and actin. A myosin contains the N-terminal globular head domain, the 
short neck domain, and the long C-terminal coiled-coil tail domain. The globular 
head works as a specialized adenosine triphosphatase (ATPase), responsible for 
adenosine triphosphate (ATP) binding, actin binding, and generating force from 
ATP hydrolysis. The neck domain transduces force generated by the head. And the 
fibrous tails are bundled together to form the thick filament (Figure 1g). Actin, 
together with troponin and tropomyosin, forms the thin filament. When the two 
fibers slide toward each other, the overlapped region increases, which is the mecha-
nism of muscle contraction. Similarly, when the fibers slide away from each other, 
muscles relax (Figure 1e).
2.2 Cross-bridge cycling
The filament sliding depends on cross-bridge cycling [6]. A cross-bridge refers to 
the two globular heads of myosin, which take turns to bind, pull, and detach from the 
actin fiber to achieve relative movement between the filaments. An analogy is that a 
person alternately uses two hands to pull a rope. One alteration of the hand is consid-
ered to be one cycle. There are four basic states [7] (sometimes detailed to six states 
[8]) in cross-bridge cycling. Each state corresponds to one behavior of ATP and one 
response of myosin. State 1: activation of myosin head, when ATP binds to myosin, 
it is hydrolyzed to ADP and Pi (inorganic phosphate); myosin becomes the “cocked 
position.” State 2: cross-bridge formation, the activated myosin binds to actin; Pi 
is released to stabilize the binding. State 3: power stroke, ADP is released; myosin 
generates force to pull actin filament. State 4: detachment of cross bridge, another 
ATP binds to myosin; myosin disengages from actin; then State 1 is repeated. The 
continuous cross-bridge cycling allows myosin to pull actin to its tail side, resulting in 
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filament sliding and muscle contraction. At the resting state, actin’s myosin-binding 
site is blocked by troponin and tropomyosin [9] (Figure 1g). A switch mechanism is 
needed to expose and mask the myosin-binding site to regulate muscle contraction.
Figure 1. 
Muscle contraction illustrated on different structural levels in the cardiovascular system: tissue level—heart (a) 
and blood vessel (b); cell level—cardiomyocyte (c) and vascular smooth muscle cells (SMCs) (d); subcellular 
level—filament sliding in cardiomyocyte (e) and SMCs (f); and molecular level—thin and thick filament for 
cross-bridge cycling (g).
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Intracellular Ca2+ works as a secondary messenger that quickly bonds to tro-
ponin, causing a quick conformational change of troponin and tropomyosin [10]. 
Thus, the myosin-binding site on actin filaments is exposed, and cross-bridge 
cycling proceeds. Intracellular Ca2+ concentration, or [Ca2+]i, can return to a very 
low level to cease the contraction and cause relaxation by different mechanisms, 
such as extruding Ca2+ out of cells or storing cytosolic Ca2+ into sarcoplasmic 
reticulum (SR) which functions as the Ca2+ reservoir in the cardiomyocyte. Similar 
mechanisms exist in the vascular tissue. SMC layer lies in between the endothelium 
layer and adventitia. There is no organized contractile protein fibril or sarcomere 
structure in SMCs [11]. Instead, the contractile fibrous proteins along with other 
intermediate filaments form bundles that are immobilized by anchoring proteins 
onto cell cytoskeletons. These filaments distribute all over the cytoplasm and 
connect each other through anchoring proteins (dense bodies) to form a three-
dimensional network (Figure 1d and f). Unlike in cardiac muscles, actin filament 
in smooth muscles is associated with caldesmon, tropomyosin, and calmodulin 
(CaM) [12]. CaM is an important Ca2+ sensing protein, which binds and mediates 
many enzymes’ activities upon Ca2+ signaling. Caldesmon binds to actin, which 
inhibits the activity and motility of actin-myosin ATPase, and this binding is greatly 
strengthened by tropomyosin [13]. Ca2+ binds and activates CaM to uncouple the 
interaction between caldesmon and actin. Thus, actin’s myosin-binding sites are 
exposed to myosins. Different from skeleton or cardiac tissues, the contraction in 
smooth muscles also depends on phosphorylation level of myosin light chain, which 
is adjusted by the enzyme activity of CaM-dependent myosin light chain kinase 
(CaM-dependent MLCK) and myosin light chain phosphatase (MLCP) [14]. MLCK 
adds the phosphoryl group to the myosin light chain, while MLCP removes it. Thus, 
increase of [Ca2+]i also facilitates muscle contraction through enhancing myosin 
phosphorylation [15].
Cardiovascular contractility is crucial for blood pressure homeostasis, thermal 
exchanging, mass transfer, immune responses, and organ functions [16]. Impaired 
coronary artery contractility (caused by the block of blood vessel or poor dilation) 
incurs ischemia heart disease [17]. To maintain cardiomyocyte viability and vascu-
lar tones, enhancing vasodilation and restricting oxidative stress are critical.
3. NO-related cardiovascular physiology
3.1 Biosynthesis of NO
The biochemical history of NO dates back to 1860s when the therapeutic use 
of nitroglycerin became a prevalent treatment for angina and hypertension [18]. 
Consequent studies showed that relaxation of blood vessels depended on a molecule 
present in an intact endothelium lining, which was named as endothelium-derived 
relaxing factor (EDRF). In 1977, it was demonstrated that NO was the chemical 
released from nitroglycerin metabolism [19], and EDRF was later identified to 
be NO [20]. Since then, NO’s cardiovascular effect and medical applications have 
drawn great research interest.
NO biosynthesis primarily relies on the enzyme nitric oxide synthase (NOS). 
The reaction uses substrate L-arginine and oxygen to generate L-citrulline and 
NO in the presence of the cofactors, including Ca2+/CaM, reduced nicotinamide-
adenine-dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN), and tetrahydrobiopterin (BH4) [21].
NO is an excellent messenger molecule in the human body because it is a highly 
reactive free radical and a highly diffusible molecule [22]. NO is able to react with 
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various species, such as oxygen, superoxide, lipid oxygen radicals, thiols, and 
metals [23], which is the biochemical base for NO signaling. The ultimate biological 
effect of NO depends on its concentration, duration of release, and physiological 
environment [24]. NO concentration varies from subnanomolar (cell survival 
signaling) to micromolar (cytotoxic effect and apoptotic signaling) in the body 
[25]. Its small size and lipophilic characteristic allows it to move rapidly across 
cell membranes. However, NO’s effective distance is limited by its extremely high 
reactivity with species like oxygen, superoxide, and hemoglobin [23]. NO concen-
tration decreases rapidly around the NO source, which makes NO’s effect extremely 
localized (within hundreds μm).
Three different isoforms of NOS have been identified in the human body. 
Endothelial NOS (eNOS) is mainly found in vascular endothelial cells (ECs) and is 
involved in regulating vascular tone and blood clotting. It is also present in cardio-
myocytes where it mediates contractility of cardiac muscle [26]. Inducible NOS 
(iNOS) predominates in immune cells to produce large amounts of NO that aids in 
the host defense mechanisms. Examples include NO produced by macrophages and 
neutrophils when induced by lipopolysaccharide, interferon-γ, and tumor necrosis 
factor alpha [24]. Neuronal NOS (nNOS) is mainly identified in nerve cells where 
NO assists in nerve transmission. It has also been isolated from cardiomyocytes 
where NO regulates excitation contraction coupling of cardiac muscles [27]. NO 
generation by iNOS is mainly regulated at the transcription level, while eNOS and 
nNOS are constitutive NOS isoforms whose activities are Ca2+- and CaM dependent. 
Shear forces during blood flow stimulate the opening of Ca2+ channels on ECs to 
increase [Ca2+]i, resulting in eNOS activation [28]. NO biosynthesis can be inhibited 
by various chemicals that selectively bind to NOS with high affinities, such as NG-
monomethyl L-arginine (L-NMMA) and asymmetric dimethyl L-arginine [9].
S-nitrosothiols and nitrite are alternative endogenous sources of 
NO. S-nitrosothiols decompose to release NO under physiological pH and are 
formed through the reaction of NO and thiol [29]. Nitrite can be reduced to NO in 
the body through pathways involving reducing agents and proteins, such as ascorbic 
acid, thiols, hemoglobin, and myoglobin [30]. These backup NO generation path-
ways are emphasized during hypoxia and acidosis when oxygen-dependent NOS-
mediated NO production is limited.
3.2 NO-cGMP pathway
Endogenous NO has various physiological effects in the body including inhibiting 
platelet aggregation, regulating SMC proliferation, modulating immune response, 
participating in neuron signal transmission, and inducing vasodilation [25]. In the 
vascular system, NO is primarily generated by eNOS in ECs (Figure 2). Shear stresses 
induced by blood flow and chemical stimuli, known as agonists including acetyl-
choline, bradykinin, adenosine triphosphate, estrogen, and vascular growth factors, 
are able to activate eNOS [28, 31]. NO is a highly dynamic molecule that diffuses 
fast in both aqueous and lipid environment (with diffusion coefficient D = 2.07–
3.30 × 10−5 cm2/s in water and polymer matrices [32–34] at physiologically relevant 
temperatures). Thus, NO readily enters the SMCs and binds to the heme moiety of 
soluble guanylyl cyclase (sGC) to activate sGC, probably the most important protein 
target of NO. This binding causes the formation of a nitrosyl-heme complex, heme 
conformational change, and breaking-apart of sGC His105 from heme iron [35]. 
Then, an open central core is formed in porphyrin, which can accept guanosine 
triphosphate (GTP) to generate cyclic guanosine monophosphate (cGMP).
Cyclic-GMP binds and activates cGMP-dependent protein kinase (protein kinase 
G, or PKG), which can phosphorylate the downstream targets to trigger vasodilation 
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(Figure 2). This signaling pathway can be terminated by removing cGMP through 
converting cGMP to GMP by various phosphodiesterases (PDE) [35]. There are 
many types of PDE in the human body, and they play critical roles in regulating 
cardiovascular function, adrenal steroidogenesis, and phototransduction [35].
Interestingly, protein kinase A (PKA, cAMP-dependent protein kinase) and 
PKG share very similar nucleotide binding domains. Many studies have shown that 
cGMP can activate PKA downstream pathways and cAMP can also cross-activate 
PKG [36]. This cross regulation between cGMP and cAMP pathways sometimes 
complicates NO signaling, which will be shown later.
Due to NO’s vasodilation effect, NO releasing drugs such as organic nitrate, and 
nitro- and nitroso compounds have been used for treating angina pectoris, conges-
tive heart failure damage from ischemia–reperfusion, and pulmonary hyperten-
sion [37, 38]. Potent drugs also include chemicals that target members involved in 
NO-cGMP pathway. For example, Sildenafil, known as Viagra, is a PDE5 inhibitor. 
It prohibits cGMP from being hydrolyzed by PDE5 and extends the activation time 
of vasodilation to widen the blood vessel and increases blood flow into the penis to 
treat erectile dysfunction [39].
3.3 NO-induced muscle relaxation through Ca2+ signaling
To fully understand how NO causes vasodilation, it is necessary to perceive the 
relationship between NO-cGMP pathway and [Ca2+]i. At rest, extracellular Ca
2+ 
concentration is high (1–2 mM), while the cytosolic Ca2+ is over 1000 times lower 
(>1 μM) [40, 41]. In the endoplasmic reticulum (ER, or SR in cardiac muscles), Ca2+ 
concentration is also high (about 400 μM) [40]. NO modulates [Ca2+]i by control-
ling Ca2+ exchange mechanisms on both cell and SR membranes.
3.3.1 Ca2+ exchange through plasma membrane
Voltage-gated Ca2+ channels regulate [Ca2+]i through sensing electrical signals 
to allow Ca2+ entering the cell. High voltage-activated L-type channels are broadly 
found in the cardiovascular system. L-type Ca2+ channel inhibitors, such as dihy-
dropyridines, phenylalkylamines, and benzothiazepines, are a major class of drugs 
for treating CVDs [42]. The opening probability of L-type Ca2+ channel can be 
Figure 2. 
Biosynthesis of NO by eNOS and the biological effects of NO in the vascular system.
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lowered by PKG indirectly [43]. PKG phosphorylates the K+ channel and increases 
its opening probability to hyperpolarize the cell membrane [44, 45]. The hyper-
polarized cell membrane can no longer send electrical signals to activate the Ca2+ 
channel, and therefore, Ca2+ influx is inhibited. Besides PKG, high NO level also 
directly activates K+ channels to achieve aorta relaxation in a cGMP-independent 
fashion [46].
Ca2+ pumping ATPase located on the cell membrane also extrudes Ca2+ from the 
cytosol. It binds Ca2+ with a high affinity and forces Ca2+ out of the cell even when 
[Ca2+]i is very low to maintain the low [Ca
2+]i level at rest [47]. PKG can stimulate 
the Ca2+ pump, initiating the expulsion of cytosolic Ca2+ [48].
Unlike Ca2+ pump, Na+/Ca2+ exchanger is more effective in quickly removing 
cytosolic Ca2+, but its Ca2+ binding affinity is low [47]. This mechanism is crucial 
for preventing cells from the cytotoxicity of an acute high Ca2+ concentration. The 
driving force for Na+/Ca2+ exchanger is the stored sodium electrochemical gradient 
created by Na+/K+ channels. PKG can activate the Na+/K+ channel to cause more Na+ 
accumulated to indirectly facilitate Ca2+ removal [49, 50].
3.3.2 Ca2+ exchange through ER
Ca2+ pump ATPase also resides on the ER responsible for the uptake of cytosolic 
Ca2+ into the ER. NO pathway regulates ER Ca2+ pumping through phosphorylation 
of phospholamban by PKG [51]. Mainly identified in cardiac tissues, phospholam-
ban is an inhibitor of SR Ca2+ pump. Phospholamban is normally phosphorylated 
by PKA, which diminishes its inhibitory effect to Ca2+ pump [52]. Interestingly, 
in neonatal cardiomyocytes and vascular SMCs, NO pathway also demonstrated 
relaxation effect through differentially phosphorylating phospholamban [53, 54].
Inosital 1,4,5-trisphosphate (IP3) is a critical messenger molecule that can induce 
Ca2+ release from the ER reservoir. IP3 receptor resides on the ER and works as a 
chemical-activated Ca2+ channel. NO-cGMP pathway can reduce IP3 generation 
[55], and PKG can phosphorylate and inactivate IP3 receptor in vascular SMCs to 
inhibit ER Ca2+ release [35, 56].
3.3.3 Ca2+-independent muscle relaxation regulated by NO
Independent from NO-Ca2+ pathway, in SMCs NO also increases MLCP activity 
and limits MLCK activity, resulting in a dephosphorylation shift of myosin light 
chain phosphorylation balance [15]. Thus, myosin cross-bridge cycling is inhibited, 
causing smooth muscle relaxation.
4. Vascular structural integrity mediated by NO
Anatomic alterations in the cardiovascular structure directly deteriorate car-
diovascular functions. NO is a multifunctional regulator for homeostasis in the 
cardiovascular system. An intact endothelial layer is the hub for NO generation. 
Pathological changes in NO generation can trigger various local flaws that may 
progress to be systematic cardiovascular issues with time.
4.1 NO-induced alterations in endothelial permeability
Deviant NO level causes change of endothelial permeability, a key characteristic 
for mass transfer and extravasation. Interestingly, increase, decrease, and no change 
of vascular permeability due to the presence of NO have been reported. Using 
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high concentration (millimolar level) of exogenous NO donor spermine NONOate 
decreased endothelial permeability in the in vitro human umbilical vein endothelial 
cell (HUVEC) model [57]. And this effect was amplified by vitamin C, a chemical 
that increases the apparent half-life of NO. However, in the frog mesenteric capil-
lary model, inhibition of NO synthesis by L-NMMA decreased capillary perme-
ability [58]. Moreover, although NO effectively regulated basal vascular tone in the 
blood-brain barrier, it demonstrated no effect on its basal permeability [59]. Again, 
these results demonstrate that NO’s biological effect is sensitive to NO concentra-
tion, duration, and environment.
Vascular permeability is mainly determined by tightness of cell-cell junctions 
[60]. Tight junctions (TJs) and adherens junctions (AJs) are the most abundant 
interendothelial junctions. And both junctions are closely related to actin cyto-
skeleton dynamics [61] (Figure 2). TJs are composed of series of transmembrane 
proteins that anchor to the actin cytoskeleton to hold cells together. They seal the 
cells to maintain cell polarity and prevent the molecules from traveling through the 
space between cells. AJs consist of clusters of transmembrane protein cadherin, 
which is connected to actin cytoskeleton on its cytoplasmic side and binds strongly 
with cadherins residing on the neighboring cell membrane. These junctions are 
important for transmitting mechanical force between cells and reinforcing tissues. 
Since both junctions directly connect cytoskeletons, the cytoskeleton’s behavior will 
influence cell-cell junctions and thus control vascular permeability. When actin and 
myosin filaments undergo relative sliding to cause cell contraction, the cytoskele-
ton-associated membrane proteins will be pulled into the cells, and cell-cell junc-
tions are disrupted. NO mediates cell contraction by adjusting [Ca2+]i. Therefore, 
deviated NO level may cause the change of cell-cell junctions [60].
Another important downstream molecule of NO is vascular endothelial growth 
factor (VEGF) which has been extensively studied in cancer research due to its 
angiogenic effect. VEGF was initially considered as a vascular permeability factor, 
because it caused the formation of leaky capillaries [62], which is an important 
characteristic in tumor and retinopathy. Low NO level induces VEGF synthesis 
under normoxia through the transcription factor hypoxia-inducible factor 1 (HIF-1) 
[25, 63]. VEGF activates Src kinases, which further phosphorylate cadherin and 
elicit its internalization [64]. Once cells lose cadherin interactions, gaps between 
cells form and endothelial permeability is increased.
4.2 Inhibition of SMCs proliferation by NO
One distinctive characteristic of vascular SMCs is the phenotypic plasticity. 
Two most important phenotypes are contractile and synthetic. Contractile SMCs 
guarantee the good performance of muscle contraction/relaxation, while synthetic 
SMCs are highly proliferative and migratory, crucial for vascular remodeling during 
pregnancy and injury healing. Dysregulation of the phenotype transition causes 
neointima formation [65]. NO plays important roles in suppressing SMCs’ contrac-
tile to synthetic transition.
NO donors and 8-Br-cGMP showed similar effect in inhibiting SMC migration and 
proliferation, indicating NO’s inhibitory effect might be through the cGMP-dependent 
pathway [66]. SMCs overgrow when stimulated by serum and epidermal growth fac-
tor (EGF). Many studies were based on these models, though divergent results were 
reported. EGF induces SMC proliferation through mitogen-activated protein kinases 
(MAPK) pathway, also called extracellular signal-regulated kinases (ERK) pathway. 
Ras (a small GTPase) and Raf (kinase of MAPK kinase, or MAPKKK) are the critical 
upstream protein kinases in this pathway. NO blocks MAPK pathway by prohibit-
ing Raf from being activated by Ras-GTP in rat aortic SMCs. It is believed that PKG 
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phosphorylates Raf, resulting in the conformation change. Thus, Ras-GTP cannot 
recognize Raf, causing the block of MAPK pathway and the accumulation of Ras-GTP 
[67]. Meanwhile, elevation of cGMP induced by IL-1β is correlated with the activation 
of PKA, and it can be prevented by blocking NO and cGMP pathways. Interestingly, 
this effect is cAMP independent, but PKA inhibitor, not PKG inhibitor, can prevent 
the inhibition of the proliferation, indicating that cGMP-PKA cross talk plays impor-
tant roles in suppressing rat aortic SMCs’ proliferation [68].
NO-cGMP pathway may inhibit SMC growth by impairing cytoskeleton reor-
ganization. Vasodilator-stimulated phosphoprotein (VASP) is characterized as a 
substrate of both PKG and PKA [69]. It targets focal adhesions and is involved in 
actin filament formation. Cell morphology change during proliferation relies on 
VASP, and its activation relies on the phosphorylation of Ser157 primarily mediated 
by PKA [70]. However, PKG can phosphorylate Ser239 and Thr278 to impair VASP’s 
activity and inhibit actin cytoskeleton reorganization [70, 71].
NO also directly mediates proteins associated with cell cycle and cell metabo-
lism by cGMP-independent mechanisms. Cyclin A and cyclin-dependent kinase 
2 expression levels can be blunted by exogenous NO donor DETA NONOate in an 
in vitro vascular SMC model [72]. Ornithine decarboxylase (ODC) catalyzes the 
ornithine decarboxylation to form polyamines, which are necessary for cell growth 
and proliferation. ODC’s active center can be masked by nitrosylation. And NO 
biosynthesis’s intermediate product N(omega)-hydroxyarginine can inhibit ODC 
enzyme activity [73] to disrupt cell proliferation.
4.3 Prevention of thrombogenesis by NO
Thrombus formation is critical for hemostasis during injury. However, thrombus 
in blood vessels can cause stroke and heart attack. Stable thrombus reduces lumen 
size and stiffens blood vessels. Unstable thrombus may rupture with blood flow and 
block the vessel. Activation of platelet is a critical step for thrombus formation, which 
involves exocytosis processes to expose P-selectin on the platelet surface and activate 
glycoprotein IIb/IIIa. Both processes depend on the elevation of [Ca2+]i controlled 
by IP3 pathway. NO suppresses platelet activation through NO-cGMP pathway [74]. 
Although, the inhibition pathway has not been fully characterized, evidences have 
shown that cGMP-PKG blocks agonist-induced IP3 formation in platelet [75], and 
PKG can phosphorylate IP3 receptor to inhibit Ca
2+ release from the ER [35].
When the endothelium loses its integrity, there will be a local shortage of 
thromboregulators such as NO, prostacyclin, and ectonucleotidase CD 39, result-
ing in thrombogenesis [76]. Collagen and tissue factors also trigger the coagulation 
reactions [76]. The use of blood contact implant is another common source of 
thrombus. Note that, all materials are thrombogenic to some degrees. To enhance 
implant biocompatibility, an efficient method is to use NO releasing polymers to 
fabricate or surface coat the blood contacting devices (such as vascular graft/stent, 
intravascular catheter, and sensor implants). Common strategies include: physically 
incorporating NO releasing chemicals into polymer matrices, chemically linking 
NO releasing agent to polymer backbones, and developing materials that can trigger 
NO generation using endogenous NO donors circulating in the blood. By using 
the first two strategies, successful trials have been reported to achieve long-term 
(over few weeks to months) NO releasing and antithrombotic applications [77–79]. 
Good NO donors include N-diazeniumdiolate and S-nitrosothiols. Both hydrophilic 
and hydrophobic polymers that are commonly used in medical device fabrication 
have been successfully modified for NO release including poly(vinyl chloride), 
polymethacrylates, various hydrogels, polyethylene terephthalate, polyurethane, 
and silicone rubbers [77]. The third strategy directly uses endogenous NO donors as 
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the NO reservoir to catalyze NO generation from S-nitrosoglutathione or nitrite in 
the body. Currently, its main challenge is to adjust the NO releasing rate to be more 
biologically relevant.
5. Nitroso-redox balance in the cardiovascular system
Oxidative stress is always associated with ischemia reperfusion injury, dilated 
cardiomyopathy, and heart failure [80]. It is crucial to restore redox balance in the 
cardiovascular system when treating these diseases. Redox balance is governed by 
changes in the oxidative state in tissues, where addition and loss of electrons result 
in reduction and oxidation of molecules, respectively [80]. Oxygen can accept an 
electron to become reactive oxygen species (ROS). ROS are highly reactive chemical 
species that contain oxygen atoms, mostly free radicals with one or more unpaired 
electrons [81]. NO is a free radical signaling molecule. Under pathological condi-
tions, it reacts with superoxide to generate reactive nitrogen species (RNS) that 
have detrimental consequences to cells. Herein, we highlight the causes of redox 
imbalance, their functions in the cardiovascular system, and the roles they play in 
the progression of CVDs.
5.1 Biochemistry and physiology of ROS and RNS
5.1.1 ROS and oxidative stress
The electron transport chain (ETC) located in the inner membrane of mito-
chondria is crucial for energy and ROS generation (Figure 3). Normally, the final 
electron acceptor oxygen is reduced to water. However, in pathological conditions, 
electrons uncouple from the chain and react with oxygen without passing  
cytochrome c oxidase to form superoxide. Other ROS sources include NADPH 
oxidase, xanthine oxidase (XO), eNOS, and cytochrome P450s (CYP). NADPH 
oxidases belong to NOX family proteins, which transfer electrons across intracel-
lular membranes. NADPH oxidases transfer electron from NADPH to oxygen to 
form superoxide for immune responses [82, 83]. Three NOX enzymes have been 
found in the vascular wall, NOX 1, 2, and 4. NOX 1 and 2 result in the formation 
of superoxide and NOX 4 produces hydrogen peroxide (H2O2) [83]. NOX 4 is also 
present in the mitochondria and SR in cardiomyocytes [80]. XO is found in the heart 
and ECs. It catalyzes purine metabolism with superoxide and H2O2 produced. The 
activity of XO is enhanced under ischemic reperfusion injury and oscillatory shear 
stress [83, 84]. Another important source of ROS is the uncoupling of eNOS, which 
causes eNOS to produce superoxide, instead of NO. One of the reasons for eNOS 
uncoupling is the deficiency in the substrates (L-arginine and oxygen) and co-factor 
BH4 [80, 83]. Uncoupling of eNOS may explain why diabetic patients are susceptible 
to CVDs. High glucose increases arginase levels in ECs, which competes with eNOS 
for the substrate L-arginine [85]. In addition, overload of ROS in diabetes mellitus 
limits BH4 biosynthesis to further facilitate eNOS uncoupling [86]. Cytochrome 
p450s (CYP) are a group of hemoproteins similar in structure and function to eNOS 
under oxidative stresses. The catalytic activity of CYP requires oxygen and two 
electrons to form a ferrous-dioxy complex [87]. CYP is involved in the metabolism 
of cholesterol, vitamins, and arachidonic acid [88]. When there is excessive oxygen 
consumed, the enzyme uncouples, and the ferrous-dioxy complex diverts back to 
the ferric state to produce superoxide [89].
Superoxide is an anion-free radical that can produce other ROS including 
H2O2, hydroxyl radicals (
.OH), and hypochlorous acid (HClO) [80, 82, 90, 91]. 
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The spontaneous transfer of an electron to superoxide at low pH or by an enzyme 
reaction (superoxide dismutase, SOD) produces H2O2 [82, 91]. Low levels of H2O2 
(1–10 nM) induce more antioxidant molecules that protect the cells, and high levels 
(>100 nM) are likely to generate more prooxidants [91]. For example, high level 
of H2O2 was generated in neutrophils for antimicrobial effects [92, 93]. Hydroxyl 
radical can be formed from the reaction between H2O2 and superoxide (Haber Weiss 
reaction) or the breakdown of H2O2 by metal ions, Fe
2+ or Cu2+ (Fenton reaction) 
[94]. Hydroxyl radical is highly reactive. It alters DNA structure by attacking purine 
and pyrimidine bases, leading to mutations and cell damages [95]. In the pathologi-
cal myocardial tissue, it is associated with decreased contractile function, increased 
membrane phospholipid peroxidation, and heart failure [96, 97]. HClO is mainly 
produced by leukocytes when H2O2 reacts with chloride anions. It facilitates the 
removal of foreign particles and is also implicated in the progression of atheroscle-
rosis and ischemic reperfusion injury [81].
5.1.2 NO and nitrosative stress
NO acts in a diffusion- and concentration-dependent manner. Low concentra-
tions of NO (nanomolar range) have a protective role, while high NO levels (micro-
molar range) can be detrimental [98]. The majority of NO’s biological effect is 
attributed to sGC/cGMP pathway [21]. Additionally, NO acts as a signaling media-
tor through S-nitrosylation. NO can inhibit cardiac hypertrophy through nitro-
sylation of histone deacetylase 2 (HDAC2) released from chromatin [99]. HDAC2 
regulates anti-hypertrophic genes. In ischemic preconditioning (the body’s defense 
mechanism against myocardial necrosis), the S-nitrosylation of mitochondrial 
proteins protects the mitochondria from oxidative stress [100]. S-nitrosylation initi-
ates excitation contraction coupling by increasing Ca2+ uptake, and the contraction 
may be sustained through releasing of Ca2+ via SR membrane ryanodine receptors 
Figure 3. 
The major sources of ROS and RNS in the cardiovascular system.
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(RyRs) [26]. Quantitatively, when three thiols per subunit of RyR channels are 
nitrosylated, the process is reversible. However, if six or more thiols per subunit are 
nitrosylated, irreversible Ca2+ ion release occurs and can be detrimental to the car-
diac muscle [26]. In addition, when too much NO is generated during inflammation 
or sepsis, NO may cause hypovolemia due to its excessive vasodilation effect [83]. 
Furthermore, upregulation of iNOS in ECs reduces the availability of BH4 to eNOS, 
intensifying eNOS uncoupling and superoxide generation [83]. Thus, the physi-
ological role of NO can be attenuated by ROS, because NO is quickly consumed by 
superoxide before it initiates any cell response [101].
When NO collides with superoxide, peroxynitrite (ONOO−) is formed, causing 
nitrosative stress. The chemical reaction is very fast and deleterious [98]. ONOO− is 
a very strong oxidant. It reacts with proteins through tyrosine and tryptophan resi-
dues to form nitrotyrosine and nitrotryptophan, respectively [80, 98]. In diabetic 
mice, tyrosine nitration of the voltage-gated K+ channels in the vascular SMCs 
altered its dilation function, a possible mechanism of the progression of coronary 
artery disease [102]. Tyrosine nitration was also observed in cardiac myocytes 
desmin, myosin heavy chain, α-actin, and microtubules. These proteins play pivotal 
roles in maintaining cell morphology and cardiac contractility [98]. When free 
nitrotyrosine was incorporated into the carboxyl terminus of α-tubulin in micro-
tubules, altered microtubule organization and redistribution of the motor cyto-
plasmic protein dynein were observed [103]. Protein activity can also be impaired 
by oxidation of thiols to disulfide bond by ONOO− [98]. In addition, ONOO− also 
reacts with lipids to yield nitrated lipids to promote atherosclerosis, and with 
nucleic acids via guanine and the sugar phosphate backbone to damage DNA [98].
On the other hand, low concentrations of ONOO− (10–200 uM) is associated 
with tyrosine kinase-dependent signaling. ONOO− has been shown to activate 
tyrosine phosphorylation and trigger glycolysis [98]. Another example involves 
MAPK pathway, where ONOO− activates Raf-1 kinase. The MAPK pathway is 
closely associated with anti-apoptosis and cardiac hypertrophy in the cultured 
cardiomyocyte model [104].
5.2 Atherosclerosis
5.2.1 Inflammatory mechanism of atherosclerosis
Atherosclerosis is characterized by the formation of plaques that reduce the lumen 
of arteries and consequently interfere with blood flow and tissue perfusion. The 
plaque consists of the lipid core and fibrous cap. In patients with hypercholesterol-
emia, ROS and RNS oxidize low-density lipoprotein (LDL) [105]. Oxidized LDL (Ox 
LDL) initiates a cascade of events that alters the endothelial permeability and leads to 
insudation of the lipoprotein in the arterial wall. Stimulated by atheroprone signals, 
ECs express selectins and vascular cell adhesion molecule (VCAM-1) to attract 
circulating blood monocytes. Monocytes penetrate the endothelial layer;  
i.e., diapedesis occurs, and become macrophages [106]. Macrophages target Ox LDL 
for phagocytosis and become foam cells, the accumulation of which causes the forma-
tion of fatty streaks. The foam cells initiate the production of transforming growth 
factor beta (TGF-β), platelet-derived growth factor (PDGF), and fibroblast growth 
factor (FGF) in the vascular system [107, 108]. These growth factors promote the 
change of vascular SMCs from a contractile to a synthetic phenotype. SMCs migrate 
from the media layer to the intima, where they secrete a complex extracellular matrix 
to form a fibrous cap around the lipid core to stabilize the plaque [109]. The prolifera-
tion of SMCs leads to neointima hyperplasia. Thus, the vessel becomes narrowed and 
the blood flow profile alters, further aggravating endothelial dysfunction (Figure 4).
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5.2.2 Hemodynamics and atherosclerosis
In fact, disturbed blood flow at arches, branches, or bifurcations is always 
associated with the early appearance and fast development of atherosclerotic 
lesions. Blood flow influences ECs’ gene expression through “shear-stress response 
elements” in the promoters of atherosclerosis relevant genes and “mechanotrans-
ducers” that can sense the force and transduce mechanical signal into biochemical 
events within the cell. Overall, in steady laminar flow, ECs express more antithrom-
botic, anti-inflammatory, and antioxidant proteins, such as eNOS, cyclooxygen-
ase-2 (COX-2), and manganese-dependent superoxide dismutase (SOD) [110], 
while in turbulent flow, ECs show atheroprone phenotypes, which activate NF-κB 
pathways to promote the expression of cytokines and cell adhesion molecules [107].
Two highly differentially expressed transcription factors, zinc finger transcrip-
tion factor Kruppel-like factor 2 (KLF2) and nuclear factor erythroid-2-related 
factor-2 (Nrf2), were identified by comparing endothelial gene expressions under 
different hemodynamic patterns [111]. KLF-2 maintains endothelial homeo-
stasis at least in part by inhibiting local inflammation and restoring NO levels. 
Overexpression of KLF-2 blocks IL-1β-induced inflammation through inhibiting 
VCAM-1 and E-selectin expression to disturb the adhesion of immune cells [112]. In 
addition, it upregulates eNOS expression to improve vascular tones. Nrf2 is respon-
sible for regulating redox-related genes (heme oxygenase 1, ferritin heavy chain, 
NADPH dehydrogenase quinone 1, and thioredoxin reductase) to maintain vascular 
redox balance in laminar flow [111]. Remarkably, it has been shown that KLF2 and 
Nrf2 work synergistically to integrate atheroprotective signals and active antioxi-
dant responses, which may be a promising therapeutic strategy for CVDs.
5.3 Antioxidant mechanisms in nitroso-redox balance
To counteract the effect of excessive ROS and control CVD symptoms, intro-
ducing antioxidative mechanisms is an effective method (Figure 5). Increasing 
enzymes that can eliminate ROS is a commonly used strategy. For example, super-
oxide can be eliminated by dismutation of two superoxide molecules by SOD to O2 
and H2O2 [113]. H2O2 can undergo decomposition under the regulation of catalase 
and peroxiredoxin to oxygen and water [80, 114]. The thiol group in peroxiredoxins 
Figure 4. 
NO’s role in the initiation and progression of atherosclerosis.
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consumes H2O2 to form sulfenic acid, then subsequently disulfide bond [115]. 
Glutathione (GSH) peroxidase 1 uses the similar mechanism to inactivate H2O2, 
superoxide, and ONOO− in the presence of the tripeptide compound GSH. A 
prospective cohort study showed that reduced levels of GSH peroxidase 1 were 
associated with increased mortality in coronary disease patients [116].
Another effective antioxidative method is to protect redox-sensitive molecules 
from being oxidized. In the body, the thiol group on GSH can form reversible mixed 
disulfide bonds with cellular proteins under oxidative stress conditions. These disul-
fide bonds can be broken by the enzyme glutaredoxin when the surrounding cell 
environment reverts back to its normal state [80, 117]. The addition of scavengers 
to directly remove ROS/RNS can also restore the nitroso-redox balance. An example 
is the elimination of superoxide by ascorbic acid (vitamin C) [113]. By limiting 
superoxide, other reactive species can also be repressed, such as •OH and ONOO−. 
This may explain the success of the clinical trial of combining nitrate drug isosor-
bide dinitrate with hydralazine, a NADPH oxidase inhibitor, where heart failure was 
reduced by 45% [118]. By inhibiting superoxide generation from NADPH oxidase, 
ONOO− level may be reduced and NO function preserved.
The high concentrations of NO can be controlled through scavenging NO via 
oxyhemoglobin in red blood cells and myoglobin in the skeletal and heart muscle. 
These two proteins react with NO to form nitrate, which is considered as the pri-
mary method for inactivating NO in the cardiovascular system [119]. Hemoglobin 
and myoglobin can also scavenge ONOO− by their metal centers, generating nitrate 
from the reactions [120].
6. Conclusions and future outlooks
We briefly reviewed the molecular mechanisms of muscle contraction and 
relaxation in the cardiovascular system and highlighted the importance of physi-
ological and pathological effects of NO and oxidative stress. NO and ROS both 
determine the structural integrity and functionality of the cardiovascular system. 
The cardiovascular system not only nourishes cells, but also provides paths for 
immune response and systematic signaling. Drugs are transported by this system to 
the correct site for metabolic reactions. Tissue regeneration also relies on a healthy 
Figure 5. 
Maintenance of redox balance in the cardiovascular system.
15
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Nitric Oxide and Oxidative Stress-Mediated Cardiovascular Functionality: From Molecular…
DOI: http://dx.doi.org/10.5772/intechopen.82556
Author details
Weilue He1*, Maria Paula Kwesiga1, Eyerusalem Gebreyesus1 and Sijia Liu2
1 Department of Biomedical Engineering, Michigan Technological University, 
Houghton, MI, USA
2 Rehabilitation Medicine Center, West China Hospital, Sichuan University, 
Chengdu, China
*Address all correspondence to: weilueh@mtu.edu
cardiovascular system. Therefore, to maintain, the homeostasis of the cardiovas-
cular system is essential for overall health. Unfortunately, with aging, both cardiac 
function and cardiomyocyte number decline [121], and blood vessels undergo 
structural alterations [122]. Moreover, CVDs are also associated with other serious 
complications, such as diabetes, cancer, kidney failure, and inflammatory pro-
cesses. Thus, multiple therapeutic strategies are needed to treat CVDs. According 
to 2011’s American Heart Association’s guidelines for preventing CVDs, therapeutic 
strategies include smoking cessation, blood pressure control, lipid management, 
physical activity programs, diabetes management, anticoagulation, dilation 
management, and depression prevention [3]. Besides traditional pharmaceutical 
management and surgeries, new perspectives to study, diagnose, and treat CVDs 
have also shown promising results, including development of biocompatible stents 
[123], stem cells therapies [124, 125], novel devices for mechanical thrombectomy 
[126], and inflammation management [127]. Although challenges still exist, the 
implementations of research findings from different disciplines in clinical trials will 
allow us to better understand and control CVDs in the future.
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